Submission deadline: September 30, 2020, 5:00 PM Eastern Time
The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and the National Cancer Institute (NCI) are developing NCI-ComboMATCH, a successor to the NCI-MATCH / EAY131 precision medicine trial. NCI-ComboMATCH will concentrate on targeted drug combination signal-seeking studies supported by preclinical in vivo evidence.
NCI Requests Letters of Intent for Laboratories to Participate in the NCI-ComboMATCH Clinical Trial
NCI-ComboMATCH trial leadership invites applications for Clinical Laboratory Improvements Program (CLIA) certified/accredited laboratories that test tumor specimens from patients utilizing Next-Generation Sequencing (NGS) assays to participate in the NCI-ComboMATCH trial.
Effective March 11, 2020, NCI has published two solicitations in the Federal Register for the recruitment of CLIA accredited laboratories to support NCI-ComboMATCH:
These laboratories will join 30 designated laboratories already put in place last year to identify cases for NCI-MATCH. To support NCI-ComboMATCH, the designated laboratories will identify patients for the specific gene abnormalities needed for trial eligibility using assays performed as standard-of-care. Laboratories will be required to contact any of the National Clinical Trial Network sites that have activated NCI-ComboMATCH if a specimen sent from one of these sites has a gene abnormality that would potentially make the patient eligible for one of the treatment arms.